Latest Venture capital biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

by Ysios Capital

2 years ago
SpliceBio, UCB Ventures, Ysios Capital, New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund, Asabys Partners

SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The fina...

Health Tech VC firm Nina Capital, focused on Life Sciences, Closes Oversubscribed Second Fund and Announces its First Four Investments

by Professional Newco

2 years ago
Nina Capital

Nina Capital, an emerging specialist venture capital firm, today announced its second fund, started last fall, eclipsed its target size of EUR40 million in just four months. The fund will be used to c...

40 biotech participan en Health BioMatch, un encuentro de ‘citas rápidas’ organizado por BioIncubaTech y Bioga que potencia las oportunidades de negocio en el sector salud

by BioIncubaTech

2 years ago
Health BioMatch

Alrededor de 40 empresas y agentes del sector biotecnológico de Galicia, Cataluña, País Vasco, Asturias, Madrid, Aragón, Comunidad Valenciana y Portugal participaron ayer en Health BioMatch, un en...

New all-time investment record in the BioRegion, new investment funds, IPOs and unbridled acquisitions

by Biocat

2 years ago
BioRegion

Less than one month after the presentation of the 2021 BioRegion of Catalonia Report celebrating another year of record funding, SpliceBio closed one of the biggest rounds of funding in the life scien...

Ysios Capital strengthens its team with the appointment of Thomas Harth as Principal

by Ysios Capital

2 years ago
Ysios Capital

After a very active 2021, closing an oversubscribed €216M fund, 3 NASDAQ IPOs, and Sanifit’s landmark acquisition by Vifor Pharma, Ysios Capital is now focused on managing its portfolio companies ...

Medibiofarma cierra nueva ronda de financiación por valor de 1,

by Palobiofarma

2 years ago
Medibiofarma

Medibiofarma ha cerrado una ronda de financiación de 1,2 millones de euros, con el apoyo financiero de su equipo promotor y otros socios de contrastada experiencia en el ámbito de la salud y la tecn...

Integra Therapeutics closes a new investment of €1.5M with the addition of Columbus Venture Partners to seed round

by Professional Newco

2 years ago
Integra Therapeutics, Columbus Venture Partners

Integra Therapeutics, a biotechnology company that creates next generation gene writing tools, has closed an additional €1.5-million investment from venture capital firm Columbus Venture Partners. T...

Sidekick, líder en terapias de salud digitales participada por Sabadell Asabys, cierra una Serie B de $55M para impulsar su crecimiento

by Asabys Partners

2 years ago
Sidekick Health

El líder global en terapias de salud digital Sidekick Health (www.sidekickhealth.com) anuncia hoy el cierre de una ronda de financiación Serie B de $55 millones. La ronda ha sido liderada por la fir...

Crowdfunding and Venture Capital: two complementary systems for private funding in the health sector

by GENESIS Biomed

2 years ago
crowdfunding, Capital Cell, Venture Capital

As we already know, public funding is not enough to cover the entire life cycle of a company in the health sector. In fact, it is becoming increasingly common for public funding sources to contain in ...

ERC funds CRG ‘designer cytokine therapy’ project

by Centre for Genomic Regulation

2 years ago
European Research Council (ERC), Cytokines

Thanks to a new Proof of Concept Grant granted today by the European Research Council (ERC), CRG researchers led by Dr. Luis Serrano will explore new methods that improve the therapeutic effectiveness...

Minoryx raises €51 million in a round co-led by Columbus Venture Partners and Caixa Capital Risc to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

by Ysios Capital

2 years ago
Fund+, Ysios Capital, Columbus Venture Partners, Caixa Capital Risc, Minoryx, Leriglitazone

The round was co-led by Columbus Venture Partners and Caixa Capital Risc. Dr. Damià Tormo, representing Columbus Venture Partners, has joined Minoryx’s Board of Directors. CDTI, through its Innvier...

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

by Ysios Capital

2 years ago
Ysios Capital, Mineralys Therapeutics

Mineralys plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being evaluated in a Phase 2 clinical trial, called Target-H...